These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30161282)

  • 1. Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
    Inoue KI; Miyachi S; Nishi K; Okado H; Nagai Y; Minamimoto T; Nambu A; Takada M
    Mov Disord; 2019 Feb; 34(2):200-209. PubMed ID: 30161282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.
    Vivacqua G; Biagioni F; Yu S; Casini A; Bucci D; D'Este L; Fornai F
    J Chem Neuroanat; 2012 Jul; 44(2):76-85. PubMed ID: 22580273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
    Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
    Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells.
    German DC; Manaye KF; Sonsalla PK; Brooks BA
    Ann N Y Acad Sci; 1992 May; 648():42-62. PubMed ID: 1353337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1421-36. PubMed ID: 10430829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
    Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
    Bezard E; Jaber M; Gonon F; Boireau A; Bloch B; Gross CE
    Eur J Neurosci; 2000 Aug; 12(8):2892-900. PubMed ID: 10971632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
    Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S
    Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mouse MPTP model: gene expression changes in dopaminergic neurons.
    Kühn K; Wellen J; Link N; Maskri L; Lübbert H; Stichel CC
    Eur J Neurosci; 2003 Jan; 17(1):1-12. PubMed ID: 12534964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine Inhibition Differentially Controls Excitability of Substantia Nigra Dopamine Neuron Subpopulations through T-Type Calcium Channels.
    Evans RC; Zhu M; Khaliq ZM
    J Neurosci; 2017 Mar; 37(13):3704-3720. PubMed ID: 28264982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.
    Chu Y; Muller S; Tavares A; Barret O; Alagille D; Seibyl J; Tamagnan G; Marek K; Luk KC; Trojanowski JQ; Lee VMY; Kordower JH
    Brain; 2019 Nov; 142(11):3565-3579. PubMed ID: 31580415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease.
    Lv Z; Jiang H; Xu H; Song N; Xie J
    J Neural Transm (Vienna); 2011 Mar; 118(3):361-9. PubMed ID: 20556443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
    Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
    PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.